Patents by Inventor ROMAIN OLLIER

ROMAIN OLLIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 11891454
    Abstract: The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 6, 2024
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 11851502
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 26, 2023
    Assignee: Ichnos Sciences SA
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
    Patent number: 11773166
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 3, 2023
    Assignee: Ichnos Sciences SA
    Inventors: Romain Ollier, Samuel Hou, Rami Lissilaa, Darko Skegro, Jonathan Back
  • CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION
    Publication number: 20230062624
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Application
    Filed: June 9, 2022
    Publication date: March 2, 2023
    Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
  • T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20220213227
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 7, 2022
    Applicant: Ichnos Sciences SA
    Inventor: Romain OLLIER
  • PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20210171661
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: July 17, 2020
    Publication date: June 10, 2021
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
  • Antibodies that bind to CCR6 and their uses
    Patent number: 10640564
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: May 5, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Rami Lissilaa, Adrian Walmsley, Stanislas Blein, Romain Ollier, Samuel Hou, Jeremy Loyau
  • T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20200102403
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: July 16, 2019
    Publication date: April 2, 2020
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventor: Romain OLLIER
  • PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20200010568
    Abstract: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
    Type: Application
    Filed: February 14, 2019
    Publication date: January 9, 2020
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Fabrizio COMPER, Romain OLLIER, Paul WASSMANN
  • CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTION
    Publication number: 20190135918
    Abstract: The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Romain OLLIER, Samuel HOU, Rami LISSILAA, Darko SKEGRO, Jonathan BACK
  • PRODUCTION OF T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20180355064
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: May 21, 2018
    Publication date: December 13, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Samuel HOU
  • T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20180112011
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: May 6, 2015
    Publication date: April 26, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventor: Romain OLLIER
  • ANTIBODIES THAT BIND TO CCR6 AND THEIR USES
    Publication number: 20180086836
    Abstract: The present invention relates to antibodies or fragments thereof that bind to CCR6. More specifically, the present invention relates to an antibody or fragment thereof that binds to CCR6 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 190, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ ID NO: 242, SEQ ID NO: 254 or SEQ ID NO: 255 and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 191, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO: 246 or SEQ ID NO: 256, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 35, SEQ ID NO: 247, SEQ ID NO: 248 or SEQ ID NO:257 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 36 or SEQ ID NO: 192 or SEQ ID NO: 193.
    Type: Application
    Filed: October 19, 2015
    Publication date: March 29, 2018
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Rami LISSILAA, Adrian WALMSLEY, Stanislas BLEIN, Romain OLLIER, Samuel HOU, Jeremy LOYAU
  • ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
    Publication number: 20170218087
    Abstract: The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies. More specifically, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG4 heavy chain constant region which exhibit altered exchange properties.
    Type: Application
    Filed: September 14, 2016
    Publication date: August 3, 2017
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Publication number: 20170145115
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: June 23, 2016
    Publication date: May 25, 2017
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Patent number: 9493563
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: November 15, 2016
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
  • ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
    Publication number: 20160319027
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: April 6, 2016
    Publication date: November 3, 2016
    Inventors: Stanislas BLEIN, Romain OLLIER, Darko SKEGRO, Adrian WALMSLEY, Harald MOTTL
  • PURIFICATION OF HETERO-DIMERIC IMMUNOGLOBULINS
    Publication number: 20150239991
    Abstract: The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
    Type: Application
    Filed: September 25, 2013
    Publication date: August 27, 2015
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Stanislas Blein, Fabrizio Comper, Romain Ollier, Paul Wassmann
  • ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF
    Publication number: 20150183885
    Abstract: The present invention relates generally to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies and methods of treatment with anti-TrkA antibodies. In one aspect, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties for use in methods of treating neuroma and/or bone associated pain.
    Type: Application
    Filed: December 5, 2014
    Publication date: July 2, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Adrian Walmsley, Harald Mottl
  • Production of T cell retargeting hetero-dimeric immunoglobulins
    Publication number: 20150133640
    Abstract: The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 14, 2015
    Inventors: Stanislas BLEIN, Romain Ollier, Darko Skegro, Samuel Hou